Astrazeneca

FromAstraZeneca ([email protected])
Subject (150)Calquence plus obinutuzumab demonstrated sustained survival benefit in 1st-line chronic lymphocytic leukaemia with 90% of patients surviving five year
Preheader (150)Calquence plus obinutuzumab demonstrated sustained survival benefit in 1st-line chronic lymphocytic leukaemia with 90% of patients surviving five year
Typography
Arial
Colors
Text Analysis
Body Words189
Subject Words19
Body Emojis1
Subject Emojis
Media Analysis
Text Links8
Image Links4
Total Links12
Images7
Technical Metrics
Performance
HTML Size, Kb
Pixel Length, px836 px
X-Spam Score0.4
Preheader OptimizedNo
Timing
Day of WeekFriday
TimeEvening

Calquence plus obinutuzumab demonstrated sustained survival benefit in 1st-line chronic lymphocytic leukaemia with 90% of patients surviving five year

Calquence plus obinutuzumab demonstrated sustained survival benefit in 1st-line chronic lymphocytic leukaemia with 90% of patients surviving five year
Calquence plus obinutuzumab demonstrated sustained survival benefit in 1st-line chronic lymphocytic leukaemia with 90% of patients surviving five year